Mucopolysaccharidosis IIIB therapeutic - Dorphan
Latest Information Update: 06 Sep 2023
Price :
$50 *
At a glance
- Originator DORPHAN S.A.
- Class Imino sugars; Pharmacological chaperones
- Mechanism of Action Hexosaminidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Mucopolysaccharidosis III
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Mucopolysaccharidosis III in Switzerland (unspecified route) (Dorphan website, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in Switzerland
- 15 Jul 2016 Mucopolysaccharidosis IIIB therapeutic - Dorphan is available for licensing as of 15 Jul 2016. http://www.dorphan.com/